DMBA-Induced Breast Cancer Model Service

The DMBA-induced breast cancer model has anchored hormonal mammary carcinogenesis research since 1961, pairing ductal adenocarcinoma histology with estrogen- and progesterone-receptor-positive, hormone-dependent growth that recapitulates a major human disease subtype. Alfa Cytology operates this historic platform to contemporary standards, delivering controlled single-dose carcinogen administration, scheduled palpation-based tumor tracking, hormone-accelerated designs, and full histopathological and receptor profiling for chemoprevention and endocrine-therapy programs.

Overview of DMBA-Induced Breast Cancer Model

In 1961 Charles Huggins administered a single dose of 7,12-dimethylbenz[a]anthracene to Sprague-Dawley rats and produced the first chemically induced rat mammary cancer model, a system that has since generated an unmatched literature on hormone-dependent breast carcinogenesis. DMBA is a polycyclic aromatic hydrocarbon that requires hepatic cytochrome-P450 metabolism before it can act; its activated metabolites reach the mammary epithelium through the circulation, where they attack the proliferating terminal end buds of the pubertal gland, an age window that explains why the standard protocol uses females at 50–55 days of age. The induced tumors are of ductal origin, display the histopathological features of adenocarcinomas, and distribute preferentially across the thoracic gland pairs.

Fig 1. Histopathology and immunohistochemistry of DMBA-induced mammary carcinoma in Trp53+/− BALB/c mice: H&E, ERα, pERK1/2, pAKT and β-catenin staining with a summary table of marker expression. (Machida, Yukino, et al., 2021)

The model's defining virtue is hormonal fidelity. Roughly 60–90% of DMBA-induced rat mammary tumors are estrogen and progesterone receptor positive, and they regress after ovariectomy, endocrine ablation, or hormone antagonist treatment, mirroring the hormone-dependent subset of human breast cancer and making the system the historical proving ground for antiestrogens and antiprolactin agents. Operationally it is economical and quantitatively rich: a single oral gavage of 20 mg DMBA in oil produces near-complete tumor incidence with mean latencies of around three months, while weekly palpation yields rigorous incidence, multiplicity, latency, and growth-rate datasets. Tumor output is exquisitely diet-sensitive, rising on high-fat regimens and falling under agents from celecoxib to inositol hexaphosphate, and a widely adopted refinement accelerates tumorigenesis with a timed-release medroxyprogesterone acetate pellet, compressing timelines for rapid screening. Although the tumors rarely metastasize, their hormone dependence, human-like glandular organization, and chemoprevention-friendly design keep the DMBA model indispensable for preclinical studies conducted in vivo.

Principles of DMBA-Induced Breast Cancer Model Construction

Successful DMBA mammary studies rest on four cornerstones: precise age timing that exploits the terminal-end-bud window, metabolic activation chemistry, hormonal regulation of tumor growth, and disciplined quantitative palpation. The governing elements are tabulated below.

Our Services

Because the DMBA model's value lies in its quantitative discipline, Alfa Cytology treats every engagement as a measurement program first: written palpation schedules, caliper-standardized volume formulas, hormone-dependence assays, and receptor profiling are built into each protocol before the first rat is dosed.

Workflow of DMBA-Induced Breast Cancer Model Construction

The DMBA mammary study is a model of parsimony, one carcinogen dose followed by months of quantitative palpation, yet every step must be standardized to preserve comparability across cohorts. The operational sequence is as follows.

1. Study design and cohort configuration: The sponsor's objectives determine group sizes, whether the classic 20-week adenocarcinoma design or the compressed MPA-accelerated design is used, and any chemoprevention, endocrine-therapy, or dietary arms.
2. Animal receipt and acclimatization: Virgin female Sprague-Dawley rats at 45–55 days of age are habituated for at least one week; body weights are recorded to confirm the target developmental window for dosing.
3. Randomization and baseline assessment: Animals are randomized by weight across groups, and baseline general health is documented; fasting conditions are applied where the protocol specifies to ensure consistent carcinogen absorption.
4. DMBA administration: DMBA is dissolved fresh in the protocol-specified oil vehicle and administered as a single oral gavage at 15–20 mg per rat under light anesthesia, with post-dose observation for any acute reactions.
5. MPA pellet implantation (accelerated designs): In accelerated protocols, a timed-release MPA pellet is implanted subcutaneously approximately four weeks after DMBA, and animals enter a compressed observation window of roughly 60 days.
6. Scheduled palpation and tumor tracking: Animals are palpated weekly or twice weekly beginning four to eight weeks after dosing; every palpable mass is recorded with date of first detection, location across the six gland pairs, and biweekly caliper measurements for volume and growth-rate calculations.
7. Test article administration: Chemopreventive agents, endocrine modulators, or candidate therapeutics are administered on the sponsor-defined schedule, with dosing windows chosen to separate anti-initiation, anti-promotion, and anti-growth mechanisms.
8. Endpoint necropsy and analysis: At the termination time point or upon humane endpoints, animals are euthanized, tumors are excised, counted, weighed, and fixed; histopathology confirms adenocarcinoma diagnosis and grade, ER/PR immunohistochemistry profiles hormone dependence, and adjacent mammary tissue is preserved for molecular analyses.

Fig 2. DMBA-Induced Breast Cancer Model Construction Workflow.

Case Study-DMBA-Induced Breast Cancer Model Development

Alfa Cytology has conducted DMBA-based preclinical programs spanning dietary chemoprevention, COX-2 pathway inhibition, endocrine intervention, and natural-product evaluation, employing both the classic latency design and the MPA-accelerated configuration for rapid screening. These engagements have delivered rigorous latency, incidence, multiplicity, and growth-rate datasets, hormone-dependence characterization by ER/PR immunohistochemistry, and supporting oxidative stress and apoptotic marker analyses, all generated under harmonized palpation and measurement protocols. Prospective partners are welcome to request further information on representative study designs and data outputs under appropriate confidentiality arrangements.

Why Choose Alfa Cytology?

The DMBA model's sixty-year legacy is a promise that Alfa Cytology honors through measurement discipline and endocrine-domain expertise.

• Regimen flexibility spanning the classic single-dose design and the compressed MPA-accelerated design.
• Strict age-window dosing at the validated 50–55 day sensitive period.
• Standardized caliper-based tumor volume and growth-rate reporting across all cohorts.
• Integrated hormone-dependence characterization through ER/PR immunohistochemistry and ovariectomy-response options.
• Diet-programming expertise that turns nutritional modulation into a controlled variable.
• Ph.D.-level study direction with single-point accountability from protocol to final report.

Contact Us

For a breast cancer platform whose hormone dependence and quantitative pedigree have guided endocrine research for generations, Alfa Cytology is ready to serve as your execution partner. Contact us or reach out to our scientific team today to design your DMBA-induced breast cancer study and receive a customized quotation aligned with your preclinical program.

For research use only. Not intended for any clinical use.